Dr. Michael R. Shafique, pleural mesothelioma doctor

Michael R. Shafique

Medical Oncologist

Dr. Michael Shafique joined the H. Lee Moffitt Cancer Center in Tampa as a medical oncologist focusing on thoracic malignancies and how best to treat them with the latest advances in immunotherapy.

Get in touch

About Michael R. Shafique

Accolades
  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Board Certified icon

    Board Certified in Internal Medicine

  • Research Excellence icon

    Excellence in Research

  • Immunotherapy icon

    Immunotherapy

  • Works for Specialty Center icon

    Works for Specialty Center

Dr. Michael R. Shafique handles mostly cases of lung cancer and malignant pleural mesothelioma for Moffitt’s Thoracic Oncology Program, utilizing a background in hematology and clinical research.

“At Moffitt, I am passionate about helping guide patients through the complex care that is associated with a cancer diagnosis,” he said. “We develop a personalized plan of care, with the help of thoracic surgeons and radiologists, that fits each individual.”

Shafique is instrumental in evaluating targetable genetic mutations in each patient, then developing a personalized plan to attack the cancer.

“I see many patients with advanced-stage lung cancers,” he said. “The goal is finding how best to utilize immunotherapy to treat these diseases.”

Leader in Immunotherapy Research

Although chemotherapy remains the standard of care with most thoracic malignancies, novel immunotherapy drugs are now being utilized instead of, or alongside traditional treatment.

Immunotherapy involves activating a patient’s immune system to fight the cancer without the nasty side effects that often come with chemotherapy.

He often recruits patients to enroll in clinical trials, giving them access to cutting-edge treatments that otherwise would not be available.

Three of those clinical trials involve the treatment of mesothelioma, one of which is exploring the use of an immunotherapy combination of Opdivo (nivolumab) and Cyramza (ramucirumab).

He co-authored a 2019 study with Dr. Tawee Tanvetyanon — another Moffitt oncologist — that compared the use of the immunotherapy drug Keytruda (pembrolizumab) for lung cancer patients with a combination of the drug and chemotherapy.

Expert Opinion on Biological Therapy published the study that concluded patients with higher levels of the cell-surface protein PD-L1 benefited from the immunotherapy alone. And patients with lower levels of PD-L1 were helped by the combination of the two.

Shafique co-authored a study in 2018 that examined the use of Imfinzi (durvalumab), another immunotherapy drug, as a maintenance therapy after chemotherapy for unresectable lung cancer.

The study also looked at the rationale for incorporating immunotherapy into existing treatment plans.

Graduate of University of Virginia

Before joining the Moffitt Cancer Center in 2017, Shafique did an oncology and hematology fellowship at the affiliated University of South Florida medical school.

He completed a residency in internal medicine at the Duke University Medical Center.

Shafique earned his degree at the University of Virginia School of Medicine.

Disclaimer: Dr. Michael R. Shafique has no professional affiliation with Asbestos.com.

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

Get the Best Treatment Options

Find a Doctor
Asbestos.com Mesothelioma Packet

Order Your Free Treatment Guide

Get Yours Now

Find a Mesothelioma Clinical Trial Near You

Get Help Now

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Matt Mauney, Content Writer at Asbestos.com
Edited by

2 Cited Article Sources

  1. Shafique, M., Tanvetyanon, T. (2019, March 19). Immunotherapy alone or chem-immunotherapy as front-line treatment for advanced non-small cell lung cancer.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/30657338
  2. Moffitt Cancer Center. (n.d.). Michael R. Shafique, MD. Retrieved from: https://moffitt.org/providers/michael-shafique/
  •  
  •  
  •  

Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified June 25, 2019

Get Your Free Mesothelioma Guide Chat live with a patient advocate now